U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB/A
AMENDED

  Quarterly Report Under Section 13 or 15(d) of the
    Securities Exchange Act of 1934

For the quarter ended June 30, 2000
Commission File No.  1-12178

          InnoVet, Inc.
         ----------------------------------------------
         (Name of small business issuer in its charter)

     Florida                                 59-2699441
-------------------------------     -------------------------------
(State or other jurisdiction of   (IRS Employer Identification No.)
 incorporation or organization)

    P. O. Box 145, Winter Park, Florida     32790
    ----------------------------------------------------
(Address of principal executive offices)  (Zip Code)

Issuer's telephone number               None
                              -----------------------------------


Check whether the issuer  (1) filed all reports required to be
filed by Section 13 or 15 (d) of the Exchange Act of 1934 during
the past 12 months (or for such shorter period that the registrant
was required to file such reports),  and (2) has been subject to
such filing requirements for the past 90 days.
                    Yes            No     X
                        -----           -----

As of October 31, 2000, the aggregate market value of the voting stock
held by non-affiliates of the issuer was zero.

As of October 31, 2000, the issuer had outstanding 52,044,501 shares
of its common stock.
                                 1
<PAGE>
                             INDEX

                         INNOVET, INC.

PART I.  FINANCIAL INFORMATION                                 Page
-----------------------------                                  ----

Item 1.  Financial Statements (Unaudited)

         Balance Sheets
           June 30, 2000 and December 31, 1999                  4

         Statements of Operations
           Three months ended June 30, 2000 and 1999            5
           Six months ended June 30, 2000 and 1999              6

         Statement of Stockholders' (Deficit)
           Six months ended June 30, 2000                       7

         Statement of Cash Flows
           Six months ended June 30, 2000 and 1999              8

         Notes to Consolidated Condensed Financial Statements   9

Item 2.  Managment's Discussion and Analysis of
          Financial Condition and Results of
          Operations                                            9



PART II.  OTHER INFORMATION
--------------------------

Item 1.   Legal Proceedings                                     11
Item 2.   Changes in Securities                                 11
Item 3.   Defaults upon Senior Securities                       11
Item 4.   Submission of Matters to a Vote of Securities
            Holders                                             11
Item 5.   Other Information                                     11
Item 6.   Exhibits and Reports on Form 8-K                      11


SIGNATURES                                                      12


                                    2

<PAGE>

                     PART I.  FINANCIAL INFORMATION

                     Item 1.  Financial Statements.









                                    3


<PAGE>
                               InnoVet, Inc.

                              BALANCE SHEETS
                                (Unaudited)


                                    ASSETS
<TABLE>
<CAPTION>
                              June 30,       December 31,
                                2000           1999
                             -----------     -----------
<S>                          <C>             <C>
Current assets
 Cash and cash
    equivalents              $    65,548      $    1,038

Accounts receivable, net of
    Allowance for doubtful
    Accounts of $0 for
    2000 and 1999                    -            94,446
                             -----------     -----------
  Total assets               $    65,548      $   95,484
                             ===========     ===========

                           LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current liabilities
  Compensation payable       $     -          $   40,000
  Loans from stockholder        11,000            76,000
  Accrued liabilities           74,642            40,900
  Accrued interest                 -              17,584
                             ---------       -----------
     Total current
        liabilities             85,642           174,484

Stockholders' (deficit)
 Common stock, $.001 par value,
  100,000,000 shares authorized;
   52,044,501 shares issued at
   June 30, 2000, and
   18,656,881 at December 31,
   1999                         52,045            18,657
 Capital in excess of
  par value                  18,906,735       18,856,654
 Capital representing
  stock grants                5,514,990        5,514,990
 Accumulated deficit        (24,493,864)     (24,469,301)
                             ----------      -----------
                                (20,094)         (79,000)
                             ----------      -----------
  Total liabilities and
  stockholders' (deficit)    $   65,548       $   95,484
                             ===========     ===========
</TABLE>
The accompanying notes are an integral part of these statements.


                                  4

<PAGE>

                                       InnoVet, Inc.

                                  STATEMENTS OF OPERATIONS
                                        (Unaudited)
                                 Three Months ended June 30,
<TABLE>
<CAPTION>
                                  2000           1999
                                ----------     ----------
<S>                             <C>            <C>
Revenues
  Royalty and licensing income  $     -        $     -
                                 ---------      ---------

Costs and expenses
  Selling, general and
   administrative                   14,871          1,247
  Interest expense                     -            1,577
                                 ----------      --------
                                    14,871          2,824
                                 ----------      --------

    Loss before income taxes       (14,871)        (2,824)

Provision for income taxes               -            -
                                 ----------      ---------
    Net loss                     $ (14,871)     $  (2,824)
                                  ==========    ==========
    Net loss per share           $   (0.00)     $  ( 0.00)
                                  ==========    ==========
Weighted average shares          29,786,088     18,656,881
                                 ===========    ==========
</TABLE>

The accompanying notes are an integral part of these statements.




                                 5

<PAGE>
                                    InnoVet, Inc.

                                STATEMENTS OF OPERATIONS
                                      (Unaudited)

                                  Six Months Ended June 30,
<TABLE>
<CAPTION>
                                    2000           1999
                                ----------     ----------
<S>                             <C>            <C>
Revenues
  Royalty and licensing income  $      -       $      -
                                 ---------      ---------

Costs and expenses
  Selling, general and
   administrative                   23,678          2,494
  Interest expense                     885          3,153
                                 ----------      --------
                                    24,563          5,647
                                 ----------      --------
    Loss from operations
     before income taxes           (24,563)       ( 5,647)

Provision for income taxes               -            -
                                 ----------      ---------
    Net loss                     $ (24,563)     $ ( 5,647)
                                  ==========    ==========
    Net loss per share           $   (0.00)     $   (0.00)
                                  ==========    ==========
Weighted average shares          29,786,088     18,656,881
                                 ===========    ==========

</TABLE>



The accompanying notes are an integral part of these statements.


                                 6

<PAGE>

                            InnoVet, Inc.

                  STATEMENT OF STOCKHOLDERS' (DEFICIT)

                             (Unaudited)

<TABLE>
<CAPTION>
                                                                 Total
                             Capital in   Capital                Stock-
              Common Stock    Excess of Representing Accumulated holders'
           Shares     Amount  Par Value Stock Grants Deficit     (Deficit)
         ---------- -------  ---------- ---------- ------------  -------
<S>      <C>        <C>     <C>         <C>        <C>           <C>
Balance,
January 1,
2000     18,656,881 $18,657 $18,856,654 $5,514,990 $(24,469,301) $(79,000)

Capital
representing
stock
issued for
conversion
of debt  33,387,620  33,388      50,081          -            -    83,469


Net loss         -        -           -          -      (24,563)  (24,563)
        ----------   ------  ---------- ----------  -----------   --------
Balance,
June
30, 2000 52,044,501 $52,045 $18,906,735 $5,514,990 $(24,493,864) $(20,094)
         ========== ======= =========== ==========   ==========   =======
</TABLE>

The accompanying notes are an integral part of this statement.




                                   7

<PAGE>
                                              InnoVet, Inc.

                                        STATEMENTS OF CASH FLOWS

                                                (Unaudited)

<TABLE>
<CAPTION>
                                            Six Months Ended
                                                 June 30
                                           2000          1999
Cash flows from operating activities:   ----------    ---------
<S>                                     <C>           <C>
  Net loss                              $  (24,563)   $  (5,647)
  Adjustments to reconcile net loss to
  net cash used in operating activities:
  Changes in operating assets and liabilities:
   Increase in accounts receivable          94,446          -
   Increase (decrease) in accrued
       expenses                            ( 5,373)       5,553
     Net cash (used for) provided by       --------     -------
      operating activities                  64,510          (94)
                                           --------     -------
Cash flows from financing activities:
   Proceed from shareholder loans                -        5,000
Net cash provided by financing             --------     -------
    activities                                   -        5,000
                                           --------     -------
Cash flows from investing activities:
   Net cash provided by investing          --------     -------
    activities                                   -          -
                                           --------     -------

Increase (decrease)in cash and
 cash equivalents                           64,510        4,906

Cash and cash equivalents,
beginning of period                          1,038          124

Cash and cash equivalents,                 --------     -------
end of period                           $   65,548      $ 5,030
                                           ========     =======
Supplemental disclosures of cash flow
  information:
  Cash paid during the period:
    Interest                            $        -    $     -
                                            =======     =======
    Taxes                               $        -    $     -
                                            =======     =======
</TABLE>

Non-cash financing activities:
On March 10, 2000, the Company exercised its option to convert to stock,
the $65,000 loan plus $18,469 of accrued interest to March 10, 2000
resulting in the issuance of 33,387,620 shares of common stock.



The accompanying notes are an integral part of these statements.

                                    8

<PAGE>
                                     InnoVet, Inc.

                            NOTES TO FINANCIAL STATEMENTS

                                   June 30,2000


NOTE A - BASIS OF PREPARATION

The Balance Sheets at June 30, 2000 and December 31, 1999 and the related
Statements of Operations for the three months and six months ended June 30,
2000 and 1999, Statement of Stockholders' Equity for the six months ended
June 30, 2000 and Statements of Cash Flows for the six months ended June 30,
2000 and 1999, have been prepared in accordance with the instructions for
Form 10-QSB and, therefore, do not include all information and footnotes
necessary for a fair presentation of financial position, results of operations
and changes in financial position in conformity with statements, including the
footnotes thereto in the Company's Annual Report on Form 10-KSB for the year
ended December 31, 1999.  In the opinion of management, all adjustments
considered necessary for a fair presentation of the results of operations for
the six months ended June 30, 2000 have been included.


NOTE B - GOING CONCERN

The Company has sustained substantial losses from operations in past years
and has a significant accumulated deficit.  The Company has sold off
substantially all of its operating businesses and in 1999 and 2000, the
Company's sole activity was to find a company to merge with or that will
acquire it.  The Company believes that its public shell can be made
attractive if it is able to meet its reporting requirements under the
Exchange Act and maintain its OTC Bulletin Board listing with the National
Association of Securities Dealers, Inc.  Currently,  the Company's shares are
sold in the so called "pink sheets."

    Item 2.  Management's Discussion and Analysis of Financial Condition and
             Results of Operations.

(a) Results of Operations.
    ----------------------

    (1) Three months ending June 30.  Revenues.  The Company had no revenues in
the quarter ended June 30, 2000 and also for the same period in 1999.

    Selling, general and administrative expenses.  Selling, general and
administrative expenses increased $13,624 in 2000 compared to the second
quarter of 1999.  The main reasons for the increase was the related stock
remuneration compensation expense for the Company's one employee and the
professional fees related to maintaining the Company's public shell.


                                    9

<PAGE>



    Interest expense.  Interest expense decreased $1,577 in the second quarter
2000 compared to the same quarter last year.  The decrease was mainly due to the
conversion of the note payable plus interest at March 10, 2000 into common
shares.

    The outstanding loan balance of $65,000 plus interest of $18,469 was
converted to common shares at March 10, 2000.  Subsequently, on April 26, 2000,
33,387,620 common shares were issued to Oakes, Fitzwilliams at the agreed upon
price per share of $.0025.

    (2)  Six months ending June 30.  Revenues.  The Company had no revenues for
the six months ended June 30, 2000 and also for the same period in 1999.

    Selling, general and administrative expenses.  Selling, general and admin-
istrative expenses increase $21,184 in 2000 compared to the same period in 1999.
The main expense incurred in the first six months of 2000 was $10,000 for the
related stock remuneration compensation expense for the Company's one employee.
The other expenses were related to the professional fees in order to bring
the Company's tax and securities filings current.

    Interest expense.  Interest expense decreased $2,268 in 2000 compared to
the same six months last year.  The decrease was mainly due to the conversion
of the note payable plus interest at March 10, 2000 into common shares.


    (b) Liquidity.
    --------------
 At June 30, 2000, the Company had $65,548 in cash.  This is the result of
collecting all of the outstanding SSG, Inc. receivable related to the
IVET-629 licensing agreement.

The Oakes, Fitzwilliams outstanding note was due and payable on or before
September 30, 1997 with interest at the London InterBank Offered Rate
("LIBOR") plus 4%.  Although the principal and interest on the loan were not
repaid in cash, the outstanding balance of $83,469 was converted to common
shares upon the exercise by the Company of its option per the loan agreement.
The Company effectively repaid the principal and interest by issuing shares
of its common stock to the stockholder pursuant to Regulation S under the
Securities Act at a price of $.0025 per share.

The Company had no revenues for the six months ended June 30, 2000 or in the
same period last year.  The Company currently has no sources of revenue and
minimal cash.  It is possible that the public shell may be used by an active
entity seeking public company status; however, it is uncertain if or when such
an event will occur.  If such event does not occur within a short period of
time, the Company may liquidate.




                                       10


<PAGE>


PART II.OTHER INFORMATION

Item 1.  Legal Proceedings.                                  None

Item 2.  Changes in Securities.                              None

Item 3.  Defaults Upon Senior Securities.                    None

Item 4.  Submission of Matters to a Vote of Security Holders.None

Item 5.  Other Information.                                  None

Item 6.  Exhibits and Reports on Form 8-K.                   None


                                 11


<PAGE>

SIGNATURE

Pursuant to the requirements of  the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                              InnoVet, Inc.
                              -------------
                              (Registrant)




                            /s/SCOTT P. CIELEWICH
                            ---------------------
Date:  January 20, 2000    Scott P. Cielewich, Executive Vice President and
                            Chief Financial Officer



                                   12

<PAGE>